✦ LIBER ✦

Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study

✍ Scribed by Everett E. Vokes; Sheila M. O'Brien; Nicholas J. Vogelzang; Richard L. Schiisky; Mark J. Ratain

Publisher: Springer
Year: 1993
Tongue: English
Weight: 648 KB
Volume: 32
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00735917

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Five-day infusion of fluorodeoxyuridine

Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study

✍ Everett E. Vokes; James W. Raschko; Nicholas J. Vogelzang; Elizabeth E. Warfield 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 583 KB

Phase I study of temozolomide and escala

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

✍ David N. Korones; Michal Benita-Weiss; Thomas E. Coyle; Laszlo Mechtler; Peter B 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

## Abstract ## BACKGROUND Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short‐lived. Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly

Continuous infusion of high-dose 5-fluor

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study

✍ Cornelis J. A. Punt; Jos Th. M. Burghouts; Jelle J. Croles; Peter A. van Liessum 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

A phase I study of sequential administra

A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors

✍ Caio M. S. Rocha Lima; Carlo V. Catapano; Daniel Pacheco; Carol A. Sherman; Greg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND Based on preclinical findings and on the clinical antitumor efficacy of sequential paclitaxel/topotecan and topotecan/etoposide, the authors sought to define the maximum tolerated doses (MTDs) and dose‐limiting toxicities (DLTs) associated with a sequential combination of